527 Madison Ave.
258 articles with Enzo Biochem
Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod
Enzo Biochem, Inc. (NYSE:ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod.
Enzo Biochem Reports Second Fiscal Quarter and First Half 2019 Results and Reports Progress on Its Investments and Strategic Goals
Enzo Biochem, Inc. reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 at 8:30 AM E.T.
Enzo Biochem, Inc. will hold a conference call to discuss fiscal 2019 second quarter results Tuesday, March 12, 2019, at 8:30 AM E.T.
Recent Reimbursement Cuts Emphasize Value of Enzo’s Strategy
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2019 Results Tuesday, December 11, 2018 at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024
Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer
Enzo Biochem (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company’s proprietary Sphingosine Kinase 1 inhibitor drug candidate, was effective in reversing resistance to the breast cancer drug tamoxifen in a tamoxifen-resistant human breast cancer cell line.
Molecular Assay Approvals from New York State Department of Health and Planned Acquisition of New Facility Highlight Progress Advancing Growth Strategy
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal 2018 Results Tuesday, October 16, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 fourth quarter and year end results Tuesday, October 16, 2018, at 8:30 AM E.T.
Enzo Biochem to Acquire New Facility for Manufacturing and Distribution to Advance Its Diagnostic and Therapeutic Growth Strategy
Facility Will Enhance Enzo’s Ability to Produce and Distribute Its Growing Portfolio of Molecular Assays, Immunohistochemistry, Immunoassays and Immuno-oncology Products and Services
Enzo Biochem Reports Validation of Three High Quality, Low Cost Biomarkers for Detecting Cancers and Their Progression, Especially in Women’s Health Area
These cost effective, high quality primary antibodies function with our full open system workflow and complement Enzo’s strategy of introducing lower cost testing solutions for the clinical laboratory market.
Enzo Biochem Inc. reported results for the third fiscal quarter and nine months ended April 30, 2018
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2018 Results Tuesday, June 12, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 third quarter results Tuesday, June 12, 2018, at 8:30 AM E.T.
Enzo Biochem (NYSE:ENZ) today announced results for the fiscal quarter and six months ended January 31, 2018.
Enzo Biochem (NYSE:ENZ), an integrated diagnostics company, announced today validation of a cervical cancer biomarker detection test that provides a highly robust and cost-efficient solution for anatomical pathology.
Total revenue in the first fiscal quarter increased to $27.7 million, or 5%, from $26.3 million in the prior year period.
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results Friday, December 8, 2017 at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024.
Enzo Biochem Schedules Teleconference To Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 At 8:30 AM E.T.